from Ondine Biomedical Inc (LON:OBIMF)
Ondine Biomedical Inc. Announces Appointment of new Chief Financial Officer
VANCOUVER, BC / ACCESSWIRE / January 16, 2024 / Canadian life sciences company Ondine Biomedical Inc. (LON:OBI) has appointed Joseph P. ("JP") Errico as Chief Financial Officer.[i] JP will be responsible for managing and developing Ondine's finance function, as well as managing the capital markets interface, participating in discussions with large health systems and customers, and working closely with the management team on overall growth strategy, both from a financial and operational perspective.
JP has successfully founded and sold (or taken public) several medical device and pharmaceutical companies, including ElectroCore, Fastenetix, K2 Medical Systems, AD4-Pharma, E2, and SpineCore, with his patented products generating over $20 billion in sales.
Carolyn Cross, CEO and founder of Ondine commented:
"We are delighted that JP has agreed to join Ondine at this exciting time. His experience in finance, capital markets and developing medtech companies will be invaluable as we move forward with our international expansion and achieving FDA approval in conjunction with our partner HCA Healthcare."
JP Errico commented:
"Ondine represents a unique opportunity to create shareholder value while heading off one of humanity's greatest health threats, antimicrobial resistance. I am proud to be joining an excellent team of professionals as Ondine brings this critically needed technology to the world."
JP's educational background includes an undergraduate degree in Aeronautical Engineering from the Massachusetts Institute of Technology and graduate degrees in both Law and Mechanical/Materials Engineering from Duke University. He is also a trained patent attorney.
*ENDS*
Enquiries:
| Ondine Biomedical Inc. | |
| Angelika Vance, Corporate Communications | +001 (604) 838 2702 |
| Singer Capital Markets (Nominated Adviser and Joint Broker) | |
| Aubrey Powell, Asha Chotai, Sam Butcher | +44 (0)20 7496 3000 |
| RBC Capital Markets (Joint Broker) | |
| Rupert Walford, Kathryn Deegan | +44 (0)20 7653 4000 |
| Vane Percy & Roberts (Media Contact) | |
| Simon Vane Percy, Amanda Bernard | +44 (0)77 1000 5910 |
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian life science company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Ondine's nasal photodisinfection technology is approved in several jurisdictions under the brand name Steriwave®. It has been awarded the CE mark and, in the US, has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.
[i] A non-board position.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Ondine Biomedical Inc
View the original press release on accesswire.com